Precision BioSciences, Inc. (DTIL) Covered Calls
You can sell covered calls on Precision BioSciences, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DTIL (prices last updated Tue 4:16 PM ET):
| Precision BioSciences, Inc. (DTIL) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 4.82 | +0.02 | 4.60 | 5.21 | 163K | - | 0.1 |
| Covered Calls For Precision BioSciences, Inc. (DTIL) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 19 | 5 | 0.00 | 5.21 | -4.0% | -365.0% | |
| Jan 16 | 5 | 0.00 | 5.21 | -4.0% | -45.6% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
| Top 10 Open Interest For Dec 19 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TSLA covered calls | 1. | ALT covered calls | |
| 2. | SPY covered calls | 7. | SLV covered calls | 2. | EWTX covered calls | |
| 3. | IBIT covered calls | 8. | NFLX covered calls | 3. | RGTI covered calls | |
| 4. | QQQ covered calls | 9. | XLF covered calls | 4. | NNE covered calls | |
| 5. | TLT covered calls | 10. | AMZN covered calls | 5. | ABAT covered calls | |
Want more examples? DTH Covered Calls | DUG Covered Calls
